Results 91 to 100 of about 25,087 (209)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells [PDF]

, 2016
BACKGROUND: Anti-apoptotic BCL-2 family members antagonise apoptosis by sequestering their pro-apoptotic counterparts. The balance between the different BCL-2 family members forms the basis of BH3 profiling, a peptide-based technique used to predict ...
Butterworth, Michael, Cohen, Gerald M, Pettitt, Andrew, Varadarajan, Shankar   +3 more
core   +1 more source

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321

British Journal of Haematology, EarlyView.
Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu   +14 more
wiley   +1 more source

Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
We show how the loss of activity of the translation initiation factor EIF5A2—either through gene hypermethylation or pharmacologic inhibition of its highly specific hypusine post‐translational modification—induces venetoclax sensitivity in acute myeloid leukaemia (AML) cells.
Eva Crespo‐García, Carlos Quero‐Dotor, Aleix Noguera‐Castells, Laia Sancho‐Vila, Laura Martinez‐Verbo, Manel Esteller   +5 more
wiley   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia

Haematologica
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs).
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan   +22 more
doaj   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

British Journal of Haematology, EarlyView.
Elisabetta Petracci, Francesca Pavesi, Luca Castagna, Patrizia Zappasodi, Cristina Papayannidis, Calogero Vetro, Vincenzo Federico, Alessandro Cignetti, Erika Borlenghi, Nicola Fracchiolla, Luca Facchini, Luca Maurillo, Ernesta Audisio, Massimo Bernardi, Felicetto Ferrara, Francesco Lanza, Carmine Selleri, Ilenia Manfra, Claudio Cerchione, Jacopo Nanni, Andrea Davide Romagnoli, Giovanni Marconi, Chiara Zingaretti, Ivana Lotesoriere, Federica Gigli, Giovanni Martinelli, Elisabetta Todisco   +26 more
wiley   +1 more source

Improvements in Real‐World Survival in the Setting of a Recent Paradigm Shift in Acute Myeloid Leukemia Treatment

European Journal of Haematology, EarlyView.
ABSTRACT Therapeutic options for newly diagnosed (ND) acute myeloid leukemia (AML) have increased in recent years, leading to a shift in the treatment paradigm from conventional, intensive chemotherapy toward targeted and less intensive therapy. Since 2017, there has been a surge in FDA approvals for novel therapies, including small molecule inhibitors
Thuy N. Ho, Patrick Willard, Graeme F. Murray, Li Liu, Nolan Wages, Hyun Lee, Keri R. Maher   +6 more
wiley   +1 more source

Combinatorial targeting of MYC/BCL2‐associated vulnerabilities in high‐grade B‐cell lymphoma

British Journal of Haematology, EarlyView.
Giulio Donati, Paola Nicoli, Federica Miele, Paola Podini, Giorgia Dina, Angelo Quattrini, Bruno Amati   +6 more
wiley   +1 more source